Mycetoma (Madura Foot) is a chronic, progressively destructive infectious disease of the skin and subcutaneous tissues, most commonly affecting the foot. Characterized by a triad of painless swelling, sinus tract formation, and discharge containing grains, it is a neglected tropical disease with profound medical, social, and economic consequences. Although it can occur anywhere on the body, the foot is by far the most frequently involved site due to its vulnerability to traumatic inoculation, especially in populations that walk barefoot in endemic regions.
Epidemiology and Risk Factors
Mycetoma is endemic in tropical and subtropical regions, particularly within the so?called “Mycetoma Belt,” which includes countries such as Sudan, Mexico, India, Senegal, and Ethiopia. The disease disproportionately affects young adult males between the ages of 15 and 30, especially those engaged in agricultural or manual labor. According to the World Health Organization, the global burden is difficult to quantify due to underreporting, but thousands of cases have been documented across more than 100 countries.
The foot is the most commonly affected site because it is frequently exposed to soil, thorns, and other environmental materials that harbor the causative organisms. Walking barefoot is a major risk factor, as minor trauma allows fungi or bacteria to enter the subcutaneous tissues. Occupations such as farming, herding, and field labor significantly increase exposure risk.
Etiology and Pathogenesis
Mycetoma can be caused by either fungi (eumycetoma) or bacteria (actinomycetoma). More than 70 species have been implicated.
- Eumycetoma is most commonly caused by Madurella mycetomatis, especially in Africa and India.
- Actinomycetoma is caused by aerobic bacteria such as Nocardia, Streptomyces, and Actinomadura species.
The disease begins when the organism is inoculated into the skin through a penetrating injury. Over time, a chronic granulomatous inflammatory response develops, leading to the formation of grains—compact microcolonies of the pathogen. These grains become embedded in the tissues and elicit a slow but progressive inflammatory reaction that spreads to deeper structures, including muscle and bone.
Actinomycetoma tends to progress more rapidly and invade bone earlier than eumycetoma, while eumycetoma often produces larger, more destructive lesions.
Clinical Features
Mycetoma affecting the foot typically evolves over months to years. The classic clinical triad includes:
- Painless subcutaneous mass
The disease often begins as a small, firm nodule on the foot, usually on the dorsum or plantar surface. - Multiple sinus tracts
As the infection progresses, sinus tracts form and open onto the skin surface. - Discharge containing grains
The sinuses exude seropurulent fluid containing grains, which vary in color depending on the causative organism (white, yellow, red, brown, or black).
Despite the extensive tissue destruction that may occur, pain is often minimal in early stages, contributing to delayed presentation. Over time, the foot becomes swollen, deformed, and functionally impaired. In advanced cases, the infection may extend to bone, causing osteolysis, pathological fractures, and severe disability.
Secondary bacterial infection is common and may lead to increased pain, systemic illness, or even fatal septicemia if untreated.
Diagnosis
Accurate diagnosis is essential because treatment differs significantly between bacterial and fungal mycetoma. Diagnosis relies on a combination of clinical evaluation, imaging, and laboratory testing.
Clinical Examination
The presence of swelling, sinuses, and grains strongly suggests mycetoma, especially in patients from endemic regions.
Imaging
Imaging helps determine the extent of soft tissue and bone involvement.
- Ultrasound is widely used in endemic areas and can help differentiate eumycetoma from actinomycetoma based on grain appearance.
- X?rays reveal bone destruction in advanced disease.
- MRI is the preferred modality for assessing soft tissue and bone involvement due to its high sensitivity.
Laboratory Diagnosis
Laboratory confirmation involves:
- Microscopic examination of grains from sinus discharge.
- Culture of grains or biopsy specimens to identify the organism.
- Histopathology to observe characteristic grain morphology.
- PCR-based molecular testing, which is the most accurate but often unavailable in low-resource settings.
Treatment
Treatment depends on whether the infection is bacterial or fungal.
Actinomycetoma (Bacterial)
Actinomycetoma generally responds well to prolonged antibiotic therapy. Common regimens include:
- Trimethoprim-sulfamethoxazole
- Combinations with amoxicillin-clavulanate, dapsone, or aminoglycosides
Cure rates can reach 90% with appropriate therapy. Surgery is rarely required. cdc.gov
Eumycetoma (Fungal)
Eumycetoma is more difficult to treat.
- Itraconazole for 9–12 months is the current standard, though cure rates may be as low as 26%.
- Surgical excision is often necessary to remove infected tissue.
- Amputation may be required in severe or refractory cases.
- Fosravuconazole is under investigation and may offer improved outcomes.
Treatment is often lengthy, expensive, and associated with significant side effects, posing major challenges in low-resource settings.
Complications and Prognosis
If untreated, mycetoma can lead to:
- Extensive soft tissue destruction
- Bone involvement and deformity
- Loss of foot function
- Chronic disability
- Secondary bacterial infection
- Amputation
- Social stigma and economic hardship
Early diagnosis dramatically improves outcomes, but many patients present late due to lack of awareness, limited access to healthcare, and the painless nature of early disease.
Prevention and Public Health Considerations
Preventing mycetoma is challenging because the causative organisms are widespread in soil. However, several measures can reduce risk:
- Wearing protective footwear
- Avoiding barefoot walking in endemic areas
- Prompt cleaning and disinfection of wounds
- Community education on early symptoms
- Strengthening health systems for early detection and treatment
The WHO has recognized mycetoma as a neglected tropical disease since 2016, prompting increased global attention. Public health strategies emphasize surveillance, research, improved diagnostics, and access to treatment.
Mycetoma of the foot (Madura foot) is a debilitating, chronic infection that disproportionately affects vulnerable populations in tropical and subtropical regions. Its slow progression, painless early stages, and association with poverty contribute to delayed diagnosis and severe outcomes, including deformity and amputation. While bacterial mycetoma responds well to antibiotics, fungal mycetoma remains difficult to treat, highlighting the need for improved therapies and accessible diagnostic tools. Prevention through protective footwear, community education, and strengthened healthcare systems is essential. Addressing mycetoma requires a coordinated global effort to reduce its medical, social, and economic burden and to improve the lives of those affected.